Urgent Care Enterprise LLC
Urgent Care Enterprise LLC was paid $11.58M by Medicaid between Jan 2018 and Dec 2024, across 40 billing codes. Its largest line is S9083, Global fee urgent care centers — 38% of everything it billed.
ANTIOCH, TN 37013
Next to other Urgent Care Clinic/Center providers in Tennessee
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 18,279 | $582K | |
| 2019 | 18,420 | $913K | |
| 2020 | 19,344 | $1.05M | |
| 2021 | 37,872 | $2.00M | |
| 2022 | 61,055 | $2.71M | |
| 2023 | 57,631 | $2.69M | |
| 2024incomplete | 30,433 | $1.62M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| S9083 | Global fee urgent care centers | 38% | 61,021 | 55,807 | $4.38M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 21% | 38,453 | 31,743 | $2.44M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 13% | 26,462 | 22,801 | $1.51M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 11% | 20,888 | 18,007 | $1.28M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 7.6% | 11,769 | 10,401 | $882K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.2% | 13,804 | 12,434 | $374K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 1.7% | 3,200 | 2,825 | $192K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.4% | 10,013 | 8,669 | $164K |
| 87428 | 1.3% | 5,675 | 4,946 | $146K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 19,335 | 8,089 | $73K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 16,198 | 13,769 | $42K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 832 | 662 | $27K |
28 more codes
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 287 | $21K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,112 | $18K |
| 99205 | Prolong outpt/office vis | <1% | 140 | $12K |
| 99201 | <1% | 59 | $4K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 704 | $4K |
| 81025 | <1% | 1,741 | $3K | |
| 81002 | <1% | 3,739 | $2K | |
| 73610 | <1% | 283 | $2K | |
| 73630 | <1% | 214 | $1K | |
| 69209 | <1% | 121 | $915.68 | |
| 93000 | <1% | 132 | $724.74 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 162 | $717.79 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,351 | $567.08 |
| 87807 | <1% | 148 | $478.97 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 599 | $437.30 |
| 73140 | <1% | 65 | $407.55 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 434 | $254.98 |
| 73110 | <1% | 17 | $105.21 | |
| 86308 | <1% | 69 | $97.63 | |
| 73130 | <1% | 13 | $42.51 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 47 | $12.83 |
| 81003 | <1% | 139 | $10.00 | |
| 99000 | <1% | 433 | $7.78 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 16 | $1.32 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 14 | $0.96 |
| 99051 | 0% | 137 | $0.00 | |
| A6449 | Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | 0% | 79 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 129 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.